Chemistry:ETX-155
ETX-155 is a GABAA receptor positive allosteric modulator and neurosteroid which is or was under development for the treatment of depressive disorders, seizures, and fibromyalgia.[1][2][3][4][5] It is taken orally and has an elimination half-life of 24 to 40 hours.[1][3][4][5] The drug produces antidepressant-like, anxiolytic-like, and anticonvulsant effects in rodents.[4][5] Side effects of ETX-155 in humans include somnolence, fatigue, dizziness, and headache.[4][5] ETX-155 was originated by Athenen Therapeutics and is or was under development by Climb Bio and/or Eliem Therapeutics.[1][2][3] As of October 2024, development of the drug for all indications has been suspended or discontinued.[1][2][3] It reached phase 1 clinical trials prior to the suspension or discontinuation of its development.[1][2][3]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "ETX 155". 8 October 2024. https://adisinsight.springer.com/drugs/800063923.
- ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on ETX-155 with Synapse". 9 May 2026. https://synapse.patsnap.com/drug/feca97fb50594e548e74eec7563a7314.
- ↑ 3.0 3.1 3.2 3.3 3.4 "ETX-155 Drug Profile". 1 January 1900. https://pryzm.ozmosi.com/product/26513.
- ↑ 4.0 4.1 4.2 4.3 "New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development". CNS Drugs 37 (9): 781–795. September 2023. doi:10.1007/s40263-023-01025-4. PMID 37603261.
- ↑ 5.0 5.1 5.2 5.3 "ETX-155, A novel GABAA positive allosteric modulator". Presentation given at the 2022 Epilepsy Foundation Pipeline Conference. Santa Clara, CA: Eliem Therapeutics, Inc.. June 2022. https://www.youtube.com/watch?v=JuzSYOx-kGk.
 |  |
